Tongue-Swab TB Test Validated in India Shows Fast, Accurate Results in 12- 25 Minutes

IMT News Desk
IMT News Desk
· 2 min read
Portable tongue-swab TB test meets WHO accuracy targets in India, delivering fast, non-invasive results and enabling easier diagnosis

A portable, battery-operated molecular test using tongue swabs has shown strong accuracy for tuberculosis (TB) diagnosis in India, offering results within 12 to 25 minutes and promising to simplify testing in peripheral and resource-limited settings. The MiniDock MTB platform, evaluated in a multi-country study published in the New England Journal of Medicine and including Indian sites such as Christian Medical College Vellore, met World Health Organization (WHO) performance targets for near-point-of-care TB diagnostics.

In the trial involving 1,380 participants across seven countries, the device detected TB with 85.7 per cent sensitivity using sputum swabs and 79.6 per cent sensitivity with non-invasive tongue swabs, while maintaining specificity above 97.5 per cent for both sample types. Researchers noted that the platform’s performance with sputum samples was comparable to the widely used Xpert MTB/RIF Ultra assay and significantly superior to traditional smear microscopy, underscoring its potential to upgrade frontline diagnostic capacity.

Clinicians said the biggest advantage of tongue swabs is their ease and acceptability, especially for children, elderly patients and people living with HIV who often struggle to produce sputum, as well as for primary and peripheral health centres with limited infrastructure. The test’s battery operation, rapid turnaround and swab-based sampling could enable faster case detection and earlier initiation of treatment in high-burden communities, while reducing dependence on centralised laboratories.

Experts pointed out that although tongue swab sensitivity is slightly lower than sputum-based testing, the modality still meets WHO accuracy thresholds and can be integrated as part of a broader diagnostic algorithm to expand access without compromising quality. With India’s National TB Elimination Programme seeking scalable, cost-effective point-of-care tools, the validation of this tongue-swab test is seen as a significant step towards more patient-friendly and decentralised TB diagnosis, particularly in rural and hard-to-reach settings.

Read Next

India’s first focused health AI Conclave unites doctors and AI experts
Featured Article
July 10, 2026

India’s first focused health AI Conclave unites doctors and AI experts

• Global Healthcare Academy hosts HAI Conclave 2026, India’s first national platform dedicated to Healthcare and Artificial Intelligence • Landmark Bengaluru conference brings together healthcare leaders and AI experts to explore how Artificial Intelligence can make healthcare faster, safer and more accessible while keeping patients at the centre of every decision The inaugural edition of the HAI Conclave […]
Article by: IMT News Desk
Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026
News
July 10, 2026

Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026

Fischer Medical Ventures Limited (FMVL) has announced that its strategic partner, Nanyang Biologics, has achieved a major international milestone with its AI-powered molecular research platform, NYB.AI, being featured in the opening showcase at NVIDIA GTC Taiwan 2026, ahead of the keynote address by NVIDIA Founder and CEO Jensen Huang. The recognition places NYB.AI among a […]
Article by: IMT News Desk
Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs
News
July 10, 2026

Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs

Indian pharmaceutical companies are expected to report healthy revenue growth in the first quarter of FY27, but margins are likely to compress as sector profitability comes under pressure. In a recent preview note, Goldman Sachs said it anticipates around 185 basis points year-on-year margin decline for the sector in the June quarter, driven primarily by […]
Article by: IMT News Desk
Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue
News
July 10, 2026

Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue

Dr Reddy’s Laboratories has announced a delay in commercial supplies of its semaglutide product after certain batches were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the drug. The company said it has initiated an investigation into the root cause and is taking corrective measures […]
Article by: IMT News Desk